Berlin Cures

Berlin Cures possesses an unparalleled platform technology built around "BC 007," a novel drug with the potential to revolutionize the treatment of many incurable diseases caused by pathogenic functional autoantibodies (fAABs). The Berlin Cures team has been dedicated to the research of functional autoantibodies (fAABs) for over two decades and has successfully identified a molecule capable of effectively neutralizing these antibodies. BC 007 has shown promising preclinical results. In a recently completed Phase IIa trial involving patients with chronic heart failure, BC 007 demonstrated long-term autoantibody neutralization after a single administration, leading to significant improvement in cardiac function, whereas untreated patients' autoantibodies did not spontaneously disappear. Its potential as an effective therapy for Long COVID was realized when serum testing of Long COVID patients showed positive fAAB results, supported by clinical observations from four case studies. By leveraging this unique biotechnology to address the root causes of fAAB-related diseases, Berlin Cures has become one of the pioneering entities committed to fundamentally resolving this critical issue.